Bulletin
Investor Alert

Momenta Pharmaceuticals Inc.

NAS: MNTA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 13, 2020, 5:37 p.m.

/zigman2/quotes/200094979/composite

$

31.00

Change

+1.10 +3.66%

Volume

Volume 16,510

Quotes are delayed by 20 min

/zigman2/quotes/200094979/composite

Previous close

$ 28.75

$ 29.91

Change

+1.16 +4.02%

Day low

Day high

$28.10

$30.12

Open

52 week low

52 week high

$11.45

$39.88

Open

Company Description

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was found...

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

82.12

Price to Book Ratio

5.06

Enterprise Value to Sales

61.93

Total Debt to Enterprise Value

0.03

Efficiency

Revenue/Employee

202,271.00

Income Per Employee

-2,458,093.00

Receivables Turnover

2.46

Total Asset Turnover

0.04

Liquidity

Current Ratio

5.08

Quick Ratio

5.08

Cash Ratio

4.92

Profitability

Operating Margin

-1,133.30

Pretax Margin

-1,215.25

Net Margin

-1,215.25

Return on Assets

-50.45

Return on Equity

-63.37

Return on Total Capital

-56.64

Return on Invested Capital

-61.08

Capital Structure

Total Debt to Total Equity

8.75

Total Debt to Total Capital

8.04

Total Debt to Total Assets

6.43

Long-Term Debt to Equity

7.55

Long-Term Debt to Total Capital

6.94

Officers and Executives

Name Age Officer Since Title
Mr. Bruce L. Downey 71 2009 Chairman
Mr. Craig A. Wheeler 57 2006 President, Chief Executive Officer & Director
Dr. Young T. Kwon - 2011 Chief Business Officer
Dr. Santiago Arroyo 59 2017 Chief Medical Officer & Senior VP-Development
Dr. Anthony M. Manning 57 2013 Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/10/2020 Craig A. Wheeler
President & CEO; Director
2,601   Disposition at $31.21 per share. 81,177
08/10/2020 Young T. Kwon
Chief Financial & Bus. Officer
652   Disposition at $32.36 per share. 21,098
08/10/2020 Jo-Ann Beltramello
Chief HR and Inf. Officer
622   Disposition at $32.36 per share. 20,127
08/10/2020 Anthony M. Manning
Chief Scientific Officer
347   Disposition at $32.36 per share. 11,228
08/10/2020 Ian D. Fier
Chief Mfg and Program Officer
330   Disposition at $32.36 per share. 10,678
08/07/2020 Craig A. Wheeler
President & CEO; Director
5,781   Derivative/Non-derivative trans. at $0 per share. 0
08/07/2020 Young T. Kwon
Chief Financial & Bus. Officer
1,410   Derivative/Non-derivative trans. at $0 per share. 0
08/07/2020 Jo-Ann Beltramello
Chief HR and Inf. Officer
1,346   Derivative/Non-derivative trans. at $0 per share. 0
08/07/2020 Jo-Ann Beltramello
Chief HR and Inf. Officer
2,690   Derivative/Non-derivative trans. at $18.85 per share. 50,706
08/07/2020 Anthony M. Manning
Chief Scientific Officer
750   Derivative/Non-derivative trans. at $0 per share. 0
08/07/2020 Ian D. Fier
Chief Mfg and Program Officer
713   Derivative/Non-derivative trans. at $0 per share. 0
08/07/2020 Jo-Ann Beltramello
Chief HR and Inf. Officer
2,690   Disposition at $32 per share. 86,080
08/05/2020 Georges Gemayel
Director
10,000   Disposition at $33 per share. 330,000
08/05/2020 Steven C. Gilman
Director
13,000   Disposition at $32.75 per share. 425,750
08/05/2020 Santiago Arroyo
SVP, Chief Medical Officer
94   Disposition at $32.65 per share. 3,069
08/05/2020 Georges Gemayel
Director
10,000   Derivative/Non-derivative trans. at $14.84 per share. 148,400
08/05/2020 Steven C. Gilman
Director
13,000   Derivative/Non-derivative trans. at $10.63 per share. 138,190
08/04/2020 Ian D. Fier
Chief Mfg and Program Officer
24,969   Disposition at $32.76 per share. 817,984
08/04/2020 Santiago Arroyo
SVP, Chief Medical Officer
34,542   Disposition at $32.25 per share. 1,113,979
08/04/2020 Ian D. Fier
Chief Mfg and Program Officer
24,969   Derivative/Non-derivative trans. at $12.76 per share. 318,604
08/04/2020 Santiago Arroyo
SVP, Chief Medical Officer
22,500   Derivative/Non-derivative trans. at $17.2 per share. 387,000
08/04/2020 Santiago Arroyo
SVP, Chief Medical Officer
10,156   Derivative/Non-derivative trans. at $12.76 per share. 129,590
07/29/2020 Georges Gemayel
Director
10,000   Disposition at $30 per share. 300,000
07/29/2020 Steven C. Gilman
Director
10,000   Disposition at $29.7 per share. 297,000
07/29/2020 Santiago Arroyo
SVP, Chief Medical Officer
39,618   Disposition at $30 per share. 1,188,540
07/29/2020 Georges Gemayel
Director
10,000   Derivative/Non-derivative trans. at $14.84 per share. 148,400
07/29/2020 Steven C. Gilman
Director
10,000   Derivative/Non-derivative trans. at $10.63 per share. 106,300
07/29/2020 Santiago Arroyo
SVP, Chief Medical Officer
22,500   Derivative/Non-derivative trans. at $17.2 per share. 387,000
07/29/2020 Santiago Arroyo
SVP, Chief Medical Officer
10,156   Derivative/Non-derivative trans. at $12.76 per share. 129,590
07/28/2020 Santiago Arroyo
SVP, Chief Medical Officer
681   Disposition at $30 per share. 20,430
07/27/2020 Jo-Ann Beltramello
Chief HR and Inf. Officer
1,219   Disposition at $30 per share. 36,570
07/22/2020 Steven C. Gilman
Director
10,000   Disposition at $33.23 per share. 332,300
07/22/2020 Ian D. Fier
Chief Mfg and Program Officer
1,350   Disposition at $32.08 per share. 43,308
07/22/2020 Ian D. Fier
Chief Mfg and Program Officer
32,154   Disposition at $32.5 per share. 1,045,005
07/22/2020 Santiago Arroyo
SVP, Chief Medical Officer
1,939   Disposition at $32.32 per share. 62,668
07/22/2020 Steven C. Gilman
Director
10,000   Award at $10.63 per share. 106,300
07/22/2020 Ian D. Fier
Chief Mfg and Program Officer
8,031   Derivative/Non-derivative trans. at $12.76 per share. 102,475
07/21/2020 Anthony M. Manning
Chief Scientific Officer
1,745   Disposition at $34.69 per share. 60,534
07/21/2020 Anthony M. Manning
Chief Scientific Officer
194   Disposition at $34.67 per share. 6,725
07/21/2020 Santiago Arroyo
SVP, Chief Medical Officer
49,967   Disposition at $34.62 per share. 1,729,857
07/21/2020 Santiago Arroyo
SVP, Chief Medical Officer
22,500   Award at $17.2 per share. 387,000
07/21/2020 Santiago Arroyo
SVP, Chief Medical Officer
10,156   Award at $12.76 per share. 129,590
07/20/2020 Young T. Kwon
Chief Financial & Bus. Officer
1,561   Disposition at $33.95 per share. 52,995
07/20/2020 Jo-Ann Beltramello
Chief HR and Inf. Officer
1,087   Disposition at $33.95 per share. 36,903
07/20/2020 Alejandra Veronica Carvajal
Chief Legal Officer
1,087   Disposition at $33.95 per share. 36,903
07/20/2020 Anthony M. Manning
Chief Scientific Officer
49,538   Disposition at $33.91 per share. 1,679,833
07/20/2020 Anthony M. Manning
Chief Scientific Officer
1,561   Disposition at $33.95 per share. 52,995
07/20/2020 Ian D. Fier
Chief Mfg and Program Officer
1,087   Disposition at $33.95 per share. 36,903
07/20/2020 Santiago Arroyo
SVP, Chief Medical Officer
1,561   Disposition at $33.95 per share. 52,995
07/20/2020 Anthony M. Manning
Chief Scientific Officer
33,125   Derivative/Non-derivative trans. at $12.76 per share. 422,675
/news/latest/company/us/mnta

MarketWatch News on MNTA

  1. Nasdaq maintains first support, S&P 500 rattles the near-term range

    11:55 a.m. June 22, 2020

    - Michael Ashbaugh

  2. Momenta Pharmaceuticals stock price target raised to $43 from $29 at Stifel Nicolaus

    8:56 a.m. Jan. 28, 2020

    - Tomi Kilgore

  3. Momenta Pharmaceuticals stock price target raised to $50 from $29 at SunTrust RH

    8:17 a.m. Jan. 15, 2020

    - Tomi Kilgore

  4. Momenta Pharmaceuticals upgraded to overweight from neutral at J.P. Morgan

    8:10 a.m. Jan. 15, 2020

    - Tomi Kilgore

  5. These Stocks Have the Most to Gain as U.S., China Talk Trade

    7:37 p.m. Jan. 17, 2019

    - Barron's Online

  6. Momenta Pharmaceuticals upgraded to buy from hold at Stifel

    10:27 a.m. Feb. 22, 2018

    - Trey Williams

  7. Teva Tightens Belt, Now a Buy

    11:56 a.m. Jan. 9, 2018

    - Barrons Blogs

  8. Momenta shares plunge 14% on Q3 profit, revenue misses

    8:29 a.m. Nov. 1, 2017

    - Emma Court

  9. Momenta and Mylan say Orencia biosimilar didn't meet primary endpoints in early-stage trial

    8:12 a.m. Nov. 1, 2017

    - Emma Court

  10. Momenta shares plunge 14% on Q3 profit, revenue misses

    8:10 a.m. Nov. 1, 2017

    - Emma Court

  11. Momenta Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus

    7:30 a.m. Oct. 5, 2017

    - Tomi Kilgore

  12. Momenta Pharmaceuticals stock price target cut to $15 from $22 at Stifel Nicolaus

    7:30 a.m. Oct. 5, 2017

    - Tomi Kilgore

  13. Momenta Pharmaceuticals' stock plunges 26% premarket toward a 10 1/2-month low

    7:55 a.m. Oct. 4, 2017

    - Tomi Kilgore

  14. Loading more headlines...
/news/nonmarketwatch/company/us/mnta

Other News on MNTA

  1. Momenta Pharma (MNTA) Gets a Buy Rating from Stifel Nicolaus

    12:55 p.m. Aug. 10, 2020

    - SmarterAnalyst

  2. OMER, TRVN, KODK and NAVB among midday movers

    12:45 p.m. Aug. 10, 2020

    - Seeking Alpha

  3. IPO Update: Annexon Proposes IPO Terms

    2:32 p.m. July 20, 2020

    - Seeking Alpha

  4. Annexon Initiates $100 Million IPO Effort

    11:00 a.m. July 11, 2020

    - Seeking Alpha

  5. Top Ranked Momentum Stocks to Buy for July 6th

    7:32 a.m. July 6, 2020

    - Zacks.com

  6. Stifel Nicolaus Believes Momenta Pharma (MNTA) Won’t Stop Here

    5:09 p.m. June 24, 2020

    - SmarterAnalyst

  7. Loading more headlines...

At a Glance

Momenta Pharmaceuticals, Inc.

301 Binney Street

Cambridge, Massachusetts 02142

Phone

1 6174919700

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$23.87M

Net Income

$-290.06M

Employees

118.00

/news/pressrelease/company/us/mnta

Press Releases on MNTA

  1. Loading more headlines...
Link to MarketWatch's Slice.